Jonathan Tobin, Managing Director Arix Bioscience discusses Merck's $2.75 billion acquisition of VelosBio.

Jonathan Tobin, Managing Director at Arix Bioscience #ARIX and VelosBio Board Director discusses Merck's $2.75 billion acquisition of VelosBio.

Arix Bioscience plc is a global venture capital company focused on investing in and building breakthrough biotech companies around cutting edge advances in life sciences.

We collaborate with exceptional entrepreneurs and provide the capital, expertise and global networks to help accelerate their ideas into important new treatments for patients. As a listed company, we are able to bring this exciting growth phase of our industry to a broader range of investors.